Carey P
Department of Genitourinary Medicine, Royal Liverpool University Hospital, UK.
Int J STD AIDS. 2000 Jul;11(7):417-23. doi: 10.1258/0956462001916128.
Given that the long-term medical management of HIV infection necessitates making best use of all available antiretrovirals, it is somewhat surprising that the nucleoside analogue reverse transcriptase inhibitor (NRTI) zalcitabine is less commonly used. This may be due to the potential for peripheral neuropathy (PN) which has been associated with the use of this drug. The perception that zalcitabine is poorly tolerated appears to have arisen largely from the results of early monotherapy trials in patients with AIDS and low CD4 cell counts. In contrast, results of more recent studies show that PN is relatively infrequent when zalcitabine is used in combination with other antiretrovirals in current treatment settings.
鉴于对艾滋病毒感染的长期医疗管理需要充分利用所有可用的抗逆转录病毒药物，核苷类似物逆转录酶抑制剂（NRTI）扎西他滨较少被使用这一点有些令人惊讶。这可能是由于使用该药物会有发生周围神经病变（PN）的风险。扎西他滨耐受性差这一观念似乎很大程度上源于早期对艾滋病患者和低CD4细胞计数患者进行的单药治疗试验结果。相比之下，最近的研究结果表明，在当前治疗环境中，当扎西他滨与其他抗逆转录病毒药物联合使用时，PN相对不常见。
